Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MYTX-011 |
Synonyms | |
Therapy Description |
MYTX-011 is an antibody-drug conjugate (ADC) comprising an antibody targeting MET conjugated to a vcMMAE payload, which potentially induces cytotoxicity against MET-expressing tumor cells and antitumor activity (Cancer Res (2023) 83 (7_Supplement): 5000). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MYTX-011 | MYTX 011|MYTX011 | MET Antibody 31 | MYTX-011 is an antibody-drug conjugate (ADC) comprising an antibody targeting MET conjugated to a vcMMAE payload, which potentially induces cytotoxicity against MET-expressing tumor cells and antitumor activity (Cancer Res (2023) 83 (7_Supplement): 5000). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05652868 | Phase I | MYTX-011 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | Recruiting | USA | GBR | FRA | ESP | AUS | 2 |